IPO
Althea Group Holdings Limited is pleased to provide its Half Year Financial Report and Appendix 4D.
Loos, France-based Genfit announced it is planning an initial public offering (IPO) to raise $100 million. Genfit is a late-stage biopharma company focused on developing therapeutics for metabolic and liver diseases. The area that has the most interest is nonalcoholic steatohepatitis, or NASH.
Evaluate recently published the Vantage Pharma, Biotech and Medtech 2018 in review report. The annual report offers insights into the previous year’s activities in biopharma and the medical device industry.
GENFIT announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its American Depositary Shares, each representing one ordinary share, in the United States, and a concurrent private placement of its ordinary shares in Europe and other countries outside of the United States and Canada.
Two pivotal Phase 3 studies of sparsentan progressing on-track to enable potential first-in-class treatment for both FSGS and IgAN
The past year, 2018, was in many ways a decisive year for Promore Pharma
Genovis has chosen to apply IFRS 16 in advance, as well as the simplification rule regarding short-term leases.
Ultragenyx Pharmaceutical Inc. announced that it has commenced an underwritten public offering of up to $250,000,000 of shares of its common stock.
Microbix Biosystems Inc., an innovator of biological products and technologies, announces the issuance of stock options under its shareholder-approved 2018 stock option plan, as part of its compensation programs to incentivize and retain its board of directors, executives, and managers.
FINCH 2 Phase 3 trial with filgotinib in rheumatoid arthritis (RA) met all primary and secondary endpoints, with consistent tolerability
PRESS RELEASES